After fulfilment of local transfer requirements and
approval of all relevant authorities, Clariant (SWX:CLN) has completed
the sale of its Pharmaceutical Fine Chemicals unit to TowerBrook
Capital Partners, L.P. on June 30th 2006 for a transaction value of
CHF 110 million.
The Pharmaceutical Fine Chemicals unit, part of the Life Science
Chemicals Division, is subsequently reported as discontinued
operation. For an easier reconciliation you will find on our Website
(Investor Relations / Media Releases and Presentations / Supplementary
Information) a restatement of the 2006 and 2005 quarterly figures.
Clariant - Exactly your chemistry.
Clariant is a global leader in the field of specialty chemicals.
Strong business relationships, commitment to outstanding service and
wide-ranging application know-how make Clariant a preferred partner
for its customers.
Clariant, which is represented on five continents with over 100
group companies, employs about 23 000 people. Headquartered in Muttenz
near Basel, it generated sales of around CHF 8.2 billion in 2005.
Clariant's businesses are organized in five divisions: Textile,
Leather & Paper Chemicals, Pigments & Additives, Functional Chemicals,
Life Science Chemicals and Masterbatches.
Clariant is committed to sustainable growth springing from its own
innovative strength. Clariant's innovative products play a key role in
its customers' manufacturing and treatment processes or else add value
to their end products. The company's success is based on the know-how
of its people and their ability to identify new customer needs at an
early stage and to work together with customers to develop innovative,
efficient solutions.
www.clariant.com